William J Burlingham, PhD
- Division of Transplantation
600 Highland Ave
Madison, WI 53792-3284
- PhD, Biology, Syracuse University, Syracuse, NY, 1979
- Postdoctoral Research Fellowship, National Cancer Institute, Mayo Clinic and Mayo Medical School, Rochester, MN, 1980-1983
Dr. Burlingham has developed a highly respected transplant basic research program that focuses on acquired immunologic tolerance. His laboratory hopes to gain insight into graft acceptance by studying transplant recipients who have survived after stopping immunosuppressive drugs.
Specifically, his research focuses on the natural exchange of soluble antigens and low numbers of white blood cells that occurs between mother and child during pregnancy and nursing. The lab’s working hypothesis is that this exchange, which leads to persistence of bone marrow-derived maternal blood cells within the offspring (“microchimerism”) may induce a “natural” form of tolerance. This tolerance, if harnessed, may allow for drug-free acceptance of transplanted grafts. Such natural tolerance has recently been shown to be the result, not of having microchimerism per se, but having a specific type of rare maternal cells capable of producing exosomes– tiny virus-like vesicles composed of lipid, protein, and nucleic acids. The goal is now to investigate how these intercellular messengers modify the host antigen presenting cells, and T cells during tolerance, with a view toward therapeutic applications.
The other major focus of Dr. Burlingham’s lab is the phenomenon of autoimmunity that develops after lung transplantation. A novel type of T Cells, called Th-17, react to collagen type V and cause inflammation and over-production of collagens causing airway blockage and graft loss. His lab is working on ways to inhibit this process by new forms of immune suppressive drugs and by increasing T regulatory cells that normally prevent autoimmune disease.
- Extracellular matrix scaffold and hydrogel derived from decellularized and delipidized human pancreas.
- Sackett SD, Tremmel DM, Ma F, Feeney AK, Maguire RM, Brown ME, Zhou Y, Li X, O'Brien C, Li L, Burlingham WJ, Odorico JS
- Sci Rep 2018 Jul 11; 8(1): 10452
- [PubMed ID: 29993013]
- Leukocyte-Associated Ig-like Receptor 1 Inhibits Th1 Responses but Is Required for Natural and Induced Monocyte-Dependent Th17 Responses.
- Agashe VV, Jankowska-Gan E, Keller M, Sullivan JA, Haynes LD, Kernien JF, Torrealba JR, Roenneburg D, Dart M, Colonna M, Wilkes DS, Burlingham WJ
- J. Immunol. 2018 Jul 15; 201(2): 772-781
- [PubMed ID: 29884698]
- A Humanized Mouse Model Generated Using Surplus Neonatal Tissue.
- Brown ME, Zhou Y, McIntosh BE, Norman IG, Lou HE, Biermann M, Sullivan JA, Kamp TJ, Thomson JA, Anagnostopoulos PV, Burlingham WJ
- Stem Cell Reports 2018 Apr 10; 10(4): 1175-1183
- [PubMed ID: 29576539]
- Specific Donor HLA-DR Types Correlate With Altered Susceptibility to Development of Chronic Lung Allograft Dysfunction.
- Haynes LD, Julliard WA, Mezrich JD, Leverson G, Meyer KC, Burlingham WJ
- Transplantation 2018 Jul; 102(7): 1132-1138
- [PubMed ID: 29360666]
- Functional characterization of human pluripotent stem cell-derived arterial endothelial cells.
- Zhang J, Chu LF, Hou Z, Schwartz MP, Hacker T, Vickerman V, Swanson S, Leng N, Nguyen BK, Elwell A, Bolin J, Brown ME, Stewart R, Burlingham WJ, Murphy WL, Thomson JA
- Proc. Natl. Acad. Sci. U.S.A. 2017 07 25; 114(30): E6072-E6078
- [PubMed ID: 28696312]